Why it matters: The pilot program in Switzerland called “Züri Can – Cannabis with Responsibility” allows pre-approved participants to purchase and consume cannabis from select pharmacies and social clubs. The program aims to study the impact of cannabis sales and its effects on consumer health.
What they are saying: The study includes 1,200 participants who had to meet specific criteria, such as living in Zurich, having prior cannabis consumption experience, and not working as professional drivers or being pregnant. Participants can choose one supply point and will receive online surveys to gather data on the effects of different cannabis strengths and models of sale.
The big picture: The pilot program was initially delayed due to project complexity but received approval earlier this year. Two cultivators, Pure Production and Swissextract, were approved to provide cannabis products for the program. Additional studies, such as the SCRIPT program, are also underway to investigate the health and social effects of regulated cannabis sales in pharmacies.
What to watch: As the pilot program progresses, researchers will collect data on the impact of cannabis sales and consumption. It will be interesting to see the results and how they may inform potential cannabis policy changes in Switzerland and other countries.
My take: The pilot program and other studies in Switzerland demonstrate a growing interest in studying the effects of cannabis and exploring alternative approaches to its regulation. By gathering data and examining different models of sale, policymakers can make more informed decisions regarding cannabis legalization and consumption. These studies are valuable in understanding the potential benefits and risks associated with cannabis use.
